UNSPSC 51461542: Medicinal tree pollen

This classification denotes a natural product which US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifiers 2A64U81OQ3, BBO1IJ3ZIW, NX974IRT8E, and M0G28FH9K1, the sources of which Integrated Taxonomic Information System classifies under Taxonomic Serial Numbers 28827, 35682, 27228, and 28811. European Medicines Agency schedules tree pollen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB55247.

UNSPSC 51461542 Medicinal tree pollen is a Commodity code that encompasses pharmaceutical and over-the-counter products distributed through state and local government procurement networks, though recent activity under this specific code shows minimal direct alignment with medicinal tree pollen as a discrete product line. State and local buyers sourcing under this taxonomy include cooperative purchasing alliances administering multi-state contracts that aggregate demand across participating state departments, counties, municipalities, and other public entities. The work involves establishing vendor relationships for pharmaceutical product supply chains, with manufacturers required to meet stringent regulatory compliance including current Good Manufacturing Practices (cGMP) and Drug Supply Chain Security Act (DSCSA) certification, maintain relationships with authorized pharmaceutical wholesalers, and provide detailed product specifications including National Drug Codes, SKUs, UPCs, and packaging configurations. Vendors must also carry substantial insurance coverage, including commercial general liability of $5,000,000 per occurrence and network security and privacy liability of $2,000,000, and agree to administrative fees and performance penalty structures.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 on January 20, 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products serving participating states including Oregon, with proposals due March 26, 2026. The evaluation weighted price competitiveness at 75 percent, with the remaining 25 percent divided among fixed pricing, administrative compliance, EDI capability, and agreement to a 3 percent administrative fee. Awarded vendors will be effective July 1, 2026 for a two-year initial term with optional extensions, and MMCAP reserves the right to make sole, dual, or multi-awards based on therapeutic considerations and member-specific needs.